GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » EV-to-FCF

Concord Biotech (BOM:543960) EV-to-FCF : (As of Apr. 10, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Concord Biotech's Enterprise Value is ₹164,661 Mil. Concord Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₹0 Mil. Therefore, Concord Biotech's EV-to-FCF for today is .

The historical rank and industry rank for Concord Biotech's EV-to-FCF or its related term are showing as below:

BOM:543960' s EV-to-FCF Range Over the Past 10 Years
Min: 0   Med: 0   Max: 95.03
Current: 95.03

During the past 5 years, the highest EV-to-FCF of Concord Biotech was 95.03. The lowest was 0.00. And the median was 0.00.

BOM:543960's EV-to-FCF is ranked worse than
91.79% of 463 companies
in the Biotechnology industry
Industry Median: 2.31 vs BOM:543960: 95.03

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-10), Concord Biotech's stock price is ₹1604.05. Concord Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹31.190. Therefore, Concord Biotech's PE Ratio (TTM) for today is 51.43.


Concord Biotech EV-to-FCF Historical Data

The historical data trend for Concord Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech EV-to-FCF Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
- - - - 87.03

Concord Biotech Quarterly Data
Mar20 Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 87.03 - - -

Competitive Comparison of Concord Biotech's EV-to-FCF

For the Biotechnology subindustry, Concord Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Biotech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concord Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Concord Biotech's EV-to-FCF falls into.


;
;

Concord Biotech EV-to-FCF Calculation

Concord Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=164660.922/0
=

Concord Biotech's current Enterprise Value is ₹164,661 Mil.
Concord Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Concord Biotech  (BOM:543960) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Concord Biotech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1604.05/31.190
=51.43

Concord Biotech's share price for today is ₹1604.05.
Concord Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹31.190.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Concord Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Concord Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Biotech Business Description

Traded in Other Exchanges
Address
Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Concord Biotech Headlines

No Headlines